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Abstract  
Background and Aims 
 Mesalazine-refractory ulcerative proctitis is common, with a significant proportion of 
the patients requiring escalation to immunomodulators or biological therapy. Three 
small preliminary cohort studies suggested good clinical efficacy for the organic arsenic 
derivative acetarsol in the management of proctitis. Our aim was to describe our 
experience on the use of acetarsol in proctitis and to review all existing evidence on its 
safety and efficacy. 
Methods 
We retrospectively reviewed clinical records of all ulcerative colitis patients exposed 
to acetarsol at Nottingham University Hospitals since 2012. Clinical response was 
determined basing on physicians’ global assessments and patients’ improvement over 
the baseline (reduction in stool frequency and rectal bleeding). Clinical remission was 
defined as total resolution of symptoms including bleeding cessation. Serum arsenic, 
C-reactive protein and fecal calprotectin levels reviewed when available. Non-
parametric analysis performed.  
Results 
28 patients (16 males) with median (range) age 39 (35) and 9 (19) years disease duration 
received acetarsol suppositories for proctitis. All had failed mesalazine or corticosteroid 
topical therapy, with 50 % having additionally failed immunomodulators. Median 
treatment duration was 70 (64) days. 16/28 were prescribed acetarsol more than once. 
67.9 % achieved clinical response and 46.4 % clinical remission. 32,1 % required 
treatment escalation to steroids, thiopurines or anti-TNF agents. 6/28 patients stopped 
acetarsol due to side effects.  
Conclusions 
Acetarsol could be an effective and safe option in the management of refractory 
proctitis. A definitive trial with long term safety follow-up is required to investigate the 
efficacy and safety of this promising drug. 
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Introduction 
Ulcerative colitis (UC) is a chronic idiopathic inflammatory condition that affects the 
colonic mucosa in a continuous fashion. Disease extension in UC is classified as 
proctitis [E1], left-sided [E2] or extensive colitis [E3], with 31% of patients having 
proctitis at presentation. During follow-up, the disease will extend in 16 % of patients 
with proctitis, with the extent of colonic involvement having a major impact on 
treatment and long-term disease prognosis. (1) 
Current European Crohn's and Colitis Organization guidelines suggest the use of topical 
mesalazine (5-ASA) preparations as first line treatment for proctitis, whilst its 
combination with oral 5-ASA or topical corticosteroids is reserved for patients with an 
inadequate response to topical 5-ASA. (2)  
A lack of response to mesalazine occurs approximately in a quarter of the patients 
treated with mesalazine and requires treatment escalation to immunomodulators or 
biological agents. Recent cohort studies report success rates of 47% and 69% for 
azathioprine and infliximab respectively, whilst similar data from randomized 
controlled trials are unavailable, as disease limited to the rectum is usually an exclusion 
in such studies. Further options are needed to treat patients with refractory proctitis. (2-
5) 
Acetarsol is a pentavalent organic derivative of arsenic for which small preliminary 
studies suggested potential benefit in the management of refractory proctitis. (6-7)  
Historically, acetarsol was effectively used in the management of protozoal infections, 
such as trichomoniasis, owing to its ability to form lethal arsenic bonds following its 
binding to protein-containing sulphydryl groups that kill the parasite. (8) However, the 
anti-infective property of acetarsol do not explain its suggested efficacy in UC. 
To date, several hypotheses have been proposed for the mode of action of acetarsol, 
possibly through its action on cellular energy pathways and DNA synthesis and repair; 
but, the exact mode of its action remains unknown. (9)  
In the form of oral and intravenous preparations, the use of acetarsol has been associated 
with significant side effects (skin reactions, hematologic disorders, acrodynia and 
jaundice) and toxicity that significantly limited its use. (10-14) However, in the form 
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of rectal preparations, the preliminary reports from UC suggested far better tolerance. 
(6-7,15) 
In our study, we describe our experience of the use of acetarsol suppositories in the 
management of ulcerative proctitis and we review all existing evidence on its safety 
and efficacy, highlighting issues and challenges for future studies.       
 
Methodology 
In November 2017, we retrospectively reviewed the electronic medical records of all 
of the adult patients who were prescribed acetarsol suppositories at the Nottingham 
University Hospital National Health Service Trust since 2012.  Patients were identified 
through the hospital pharmacy database by the lead pharmacist. The Pharmacy 
Database comprised of drug dispensing records. These records included information 
regarding the type of drug, date of dispensing, strength, dosage regimen and route of 
administration and were coded according to the WHO Anatomical Therapeutic 
Chemical (ATC) Classification System.  
All dispensing records were reviewed by the authors and all patients were screened for 
eligibility. All eligible patients had histopathological confirmed ulcerative colitis, with 
most recent endoscopy showing disease confined to the rectum. 
Patients with Crohn’s disease, pouchitis, diversion colitis or active ulcerative colitis 
beyond the 20cm from the anus, were excluded. 
Additional demographic and clinical data that were collected, included sex, age, date 
of histological diagnosis, disease location/Montreal Classification, inflammatory bowel 
disease (IBD)- related medication, repeated acetarsol prescriptions, clinical outcomes, 
endoscopic and safety reports. After the first administration of acetarsol, all patients’ 
maintained medical records were prospectively reviewed until 11/2017 for occurrence 
of adverse events.  
Clinical response was determined basing on physician’s global assessment (PGA) and 
patients’ symptomatic improvement over the baseline (reduction in stool frequency and 
bleeding reduction). Clinical remission was defined as total resolution of symptoms and 
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bleeding cessation in the absence of corticosteroid use or treatment escalation to 
immunosuppressants or biologics.  (16) 
Serum arsenic (nmol/l), serum C-reactive protein (CRP) (mg/dl) and fecal calprotectin 
levels were also reviewed if undertaken as part of standard of care.  
The study was approved as a health care evaluation by Nottingham University 
Hospitals, Clinical Quality Risk and Safety Team:18-128h and conducted in 
accordance with the Helsinki Principles for the Protection of Patient Data.  
Statistical Analysis 
Due to the small sample size, the data were assumed to be non-parametric with relevant 
analyses undertaken. Continuous data are presented as median and range, while 
categorical variables are presented as frequencies.    
The level of statistical significance was set for p values of less than 0.05. SPSS 17.0 
statistical software for windows was used for the statistical analysis. 
Results 
Patient Demographics 
From 01/2012 to 12/2015, 35 IBD patients were prescribed acetarsol suppositories and 
were screened for eligibility. One patient with diversion colitis, one with Crohn’s 
disease, one with chronic pouchitis and four UC patients that were lost during follow 
up, were excluded from subsequent analysis. Figure 1 shows the flowchart of the study 
overview. 
The final study cohort consisted of 28 UC patients (16 males; 12 females) with median 
(range) age of 39 (35) years. This included 24 patients who received acetarsol for 
ulcerative proctitis and 4 patients with more proximal disease who received acetarsol 
for residual proctitis. Population characteristics are shown in table 1.  
All patients had previously failed treatment with topical or systemic 5-aminosalicylates 
and/or steroids with 14/28 (50%) having additional exposure to thiopurines and 2/28 
(7.1 %) to oral ciclosporin. 
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The median (range) daily dose of acetarsol and treatment duration were 500 (500) mg 
and 70 days (64), respectively. 57.1 % of the population received more than one 
treatment prescription in an effort to maintain the clinical response or remission.    
Clinical response was observed in 19 patients (67.9 %) and clinical remission in 46.4 
%.  
Endoscopy before and after treatment was performed in 3 patients, with 2 patients 
(66.7%) showing endoscopic improvement over the baseline.  
After acetarsol discontinuation, 9 patients (32.1 %) needed treatment escalation [3 
(10.7%) to corticosteroids, 4 (14.3 %), thiopurines and 2 (7.1 %) to anti-TNF agents]. 
During the treatment period, serum arsenic levels were available for 9/28 patients. 
Median (range) serum arsenic level was 777 (2776) nmol/l, (normal value < 130 
nmol/l). Figure 2 shows an overall decrease in the serum arsenic levels of 6 patients 
with repeated measurements over time. 
Serum CRP levels remained unchanged and within the normal range over the 
administration of acetarsol. No data identified for fecal calprotectin. 
After the first administration of acetarsol, all patients were followed up for possible 
side effects. Median (range) follow up period was 6 (3) years. Over this period, 6/28 
patients experienced possible acetarsol-related adverse events. [2 patients had 
headache, 1 vomiting, 1 perianal pruritus and paresthesia, 1 blepharitis and 1 sweating, 
palpitations and weakness]. All short-term side-effects ceased at treatment withdrawal. 
No malignancy or long-term complications had been reported. 
Discussion 
In our manuscript, we described our tertiary-level care experience on the use of 
acetarsol suppositories in a cohort of UC patients with mesalazine refractory proctitis. 
In this refractory population, acetarsol was an effective therapy, with nearly half of the 
patients achieving clinical remission and two out of every three patients treated showing 
a clinical response. The therapeutic effect was temporary, with 57.1 % of our cohort 
requiring more than one prescription in an effort to preserve response or remission. The 
dose of acetarsol and the duration of treatment were determined exclusively by the 
treating physician, whilst the ongoing follow-up of each patient did not include the 
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routine monitoring of his/her serum arsenic levels. However, cross-sectional 
measurements of the serum arsenic levels were available for the one third of our 
population. Over the treatment period, a decreasing trend over time was observed for 
the arsenic levels, with the highest levels being recorded at the first weeks of treatment. 
The most likely reason for this observation is that acetarsol is highly absorbed through 
the friable mucosa, when the disease is active, but over time, its absorption rapidly 
drops, following the healing of the mucosa; nevertheless, detailed pharmacokinetic 
studies are needed to further investigate and validate our observations. After the first 
exposure to acetarsol, all of our patients’ records were reviewed for short- and long-
term adverse events for a median (range) period of 6(3) years. Over this period, no long-
term adverse events were identified, but 6 out of the 28 patients experienced short-term 
gastrointestinal, cardiological and neurological side effects. All side effects ceased at 
medication withdrawal. In one case, the patient required admission due to severe 
headache and increased serum arsenic levels, with his/her overall status improving 
promptly with supportive measures.  
To date, our knowledge on the use of acetarsol in the management of refractory UC 
proctitis is limited to two small studies. (6-7) Nearly three decades ago, Forbes et al. 
studied for the first time the efficacy of acetarsol suppositories in a cohort of UC 
patients with mesalazine refractory proctitis. In their open label trial, 10 patients 
received acetarsol suppositories 250mg twice daily for a period of 4 weeks, with their 
serum arsenic levels being prospectively monitored. Within 2 weeks, proctitis resolved 
clinically and endoscopically in 90% patients. Other than an excellent response to the 
acetarsol, this study showed that the arsenic is systematically absorbed by the inflamed 
intestinal mucosa, with the highest arsenic levels being recorded at the first week of 
treatment, similarly to our study.  However, in 30% of the patients, the serum arsenic 
levels remained elevated after 4 weeks. The authors did not find any clinical 
consequence from this finding, but long-term therapy with acetarsol was not 
recommended.  (7) 
Recently, another cohort study from another center in the United Kingdom also looked 
at the efficacy of acetarsol in the management of proctitis. In this study, Kiely et al., by 
retrospectively reviewing the medical records of 39 IBD patients over a 6-year period, 
found that acetarsol was effective in 26 out of the 39 patients of their cohort, with one 
patient developing superficial dermatitis 1 week after commencing acetarsol, that 
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settled following the discontinuation of the drug. However, in this study, the case mix 
was heterogenous, as it additionally involved patients with refractory colonic Crohn’s 
disease and hence, represents a different cohort to our patients.  (6) 
In our study, we included only UC patients with endoscopically confined disease to the 
rectum, who had previously failed treatment with mesalazine. However, a large 
proportion (57.1%) of our patients had also failed to thiopurines or ciclosporin. In this 
population, acetarsol was found to be well tolerated and of substantial benefit, but the 
response rate was less impressive than that observed by Forbes et al., with our findings 
indicating the increased refractory nature of our exposed cohort.  
Based on these data, acetarsol might have a role in the treatment, not only of mesalazine 
refractory proctitis, but also of the residual rectal disease that’s is resistant to treatment 
with immunosuppressive and biological agents. 
Our study has limitation in particular its small cohort size and retrospective nature and 
hence, inability to collect data in a rigorous and homogenous fashion. Over the study 
period, no formal endoscopic or clinical disease activity scores were available. 
However, in the absence of more robust data, the utilization of PGA and of the rectal 
bleeding, which is the most sensitive UC symptom, in the evaluation of patients’ 
clinical response or remission, gives credence to our results. (16-17)  
In summary, our experience showed that acetarsol could be an effective and well 
tolerated option in the management of refractory proctitis. However, the evidence 
regarding its long-term efficacy and safety is limited. A definitive randomize controlled 
trial with long term safety follow-up is required to thoroughly investigate the efficacy 
and safety of this promising drug so as acetarsol to fill a niche in the UC 
pharmacotherapy.  
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